LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Appoints Laura L. Parks, Ph.D. to Board of Directors
16 juin 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., June 16, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Expands Capabilities for Growing Clinical Trial Services (CTS) Offerings
02 juin 2021 07h00 HE | Recro Pharma, Inc.
GAINESVILLE, Ga., June 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development Agreement With Astex Pharmaceuticals
18 mai 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., May 18, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
14 mai 2021 09h15 HE | Recro Pharma, Inc.
Underwriters’ Full Exercise of Option Brings Gross Proceeds to $34.5 Million EXTON, Pa., May 14, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Pricing of $30.0 Million Public Offering of Common Stock
12 mai 2021 08h30 HE | Recro Pharma, Inc.
EXTON, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Announces Proposed Public Offering of Common Stock
11 mai 2021 16h30 HE | Recro Pharma, Inc.
EXTON, Pa., May 11, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports First Quarter 2021 Financial Results
06 mai 2021 16h05 HE | Recro Pharma, Inc.
Revenues of $16.8 Million Represent an Increase of 70% Compared to Q4 2020 Revenue Multiple New Business Agreements Signed Facilities Expansion and Enhancements Continue Company to Host Conference...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro to Report Financial Results for First Quarter 2021 on May 6
29 avr. 2021 16h05 HE | Recro Pharma, Inc.
MALVERN, Pa., April 29, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Expands Development and Manufacturing Relationship With Ensysce Biosciences
15 avr. 2021 07h00 HE | Recro Pharma, Inc.
GAINESVILLE, Ga., April 15, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Reports Inducement Grants for New Staff
06 avr. 2021 07h00 HE | Recro Pharma, Inc.
MALVERN, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...